Remedi is born from the fusion of the companies Regenera Activa Worldwide and Rigenera HBW to revolutionize regenerative medicine in the treatment of injuries and osteoarthritis

Regenera Activa Worldwide and Rigenera HBW, biotech firms specializing in regenerative medicine, have joined forces under the Remedi brand to become world leaders in the field. The merger of the Spanish and Italian companies brings together 50 employees across four countries and generates annual revenues exceeding 13 million euros. This ambitious move aims for an annual growth rate of 20%.

Remedi introduces a unique concept in treating musculoskeletal diseases with the patented Rigenera® technology, supported by over 80 clinical studies. This therapy radically changes the current treatments in various therapeutic areas by offering a minimally invasive solution with rapid results for patients, achievable through a single procedure lasting less than 30 minutes without the need for hospitalization.

Alenxandre Andreu, CEO of Regenera Activa Worldwide, states that this merger "marks a new era in the field of regenerative medicine globally. We combine our know-how and commercial capabilities with the manufacturing and technological potential of Rigenera."

Dr. Antonio Graziano, CEO of Rigenera HBW, remarked, "This is a great opportunity to continue promoting this revolutionary technology, in collaboration with the scientific community, to demonstrate the new applications of Rigenera® in other medical fields that can help more and more patients."

Currently, Rigenera® technology is used by over 50,000 doctors worldwide, and in the past ten years, over 400,000 treatments have been administered using this technology, benefiting millions of patients.

A unique and revolutionary treatment

The AMT treatment procedure leverages the regenerative potential of mesenchymal stem cells or adult stem cells from the body. When transferred to similar body tissues, these cells become therapeutic, focusing solely on restoring cellular communication at the level of the damaged tissue through various biological mechanisms.

This treatment is autologous and homologous, meaning the patient acts as their own donor, thus eliminating the risk of cell rejection. Being derived from the same tissue being treated, it enhances the specificity of the treatment.

This technology has multiple applications, notably in treating osteoarthritis, a degenerative joint disease affecting cartilage, causing pain and limiting mobility. Osteoarthritis significantly impacts the population, affecting about 30% of people over 40 years old in Spain, equivalent to about 7 million people. It is the third leading cause of work disability and costs about 12,000 euros per patient annually.

Due to population aging, the prevalence of osteoarthritis has increased while traditional solutions have yet to halt its progression. Now, with this new technology, a single intervention can stop the progression of osteoarthritis, alleviate pain, and improve the quality of life.

Similarly, it also helps eliminate knee pain by slowing cartilage degradation and osteoarthritis progression, and can treat other joints affected by osteoarthritis, such as thumb osteoarthritis. The technology is particularly beneficial for high-level athletes, who, due to physical demands, experience premature degeneration.

Dr. José Miguel Casanova, Medical Director of Regenera Activa Worldwide and specialist in Sports Medicine and Aesthetic Medicine, emphasizes that "the technology is set to change the lives of millions currently suffering from osteoarthritis who lack a definitive treatment. This is Remedi's goal: to solve health problems through the regenerative power of the body and prevent disease progression."

The benefits of regenerative medicine extend beyond sports medicine and orthopedics, as the same technology can regenerate other body tissues. Rigenera® is also used in other therapeutic areas such as dermatology for hair regeneration or treating stretch marks. It offers potential uses in general medicine and trauma for complex wound healing. In this regard, Remedi collaborates with NATO on rapid healing kits and with the European Space Agency on the WHISPER project.

This collaboration, which also involves the University of Florence and the University of Pavia, addresses the challenges of treating wounds in zero-gravity conditions. The project, named "Wound Healing in Space: Problems and Perspectives for Tissue Regeneration and Engineering (WHISPER)," aims to explore the uses of Rigenera® to improve wound healing in long-duration microgravity exposure.

This study is just one example of how Remedi, through Rigenera® technology, can transform medicine as we know it today, offering a quick and innovative

REMEDI: https://remediinternational.com/en